SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Izzy who wrote (2696)11/8/1997 1:36:00 PM
From: Oliver & Co   of 6136
 
Trying to answer as short as possible:
1)No
2)Yes, they call it HAART (Highly Active Antiretroviral Therapy), but
John Mellors MD, said it would very soon be called Fairly Active
Antiretroviral Therapy (FAART)
3)Yes
4)Depending on the patients, cd4 every ~3 months, viral load once a
month until undetectable, then every 3 months. Adjust therapy based
on clinical response, specially rises on HIV RNA.

You are most wellcome.

JLL
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News